An Optimized Channel Selection Method Based on Multifrequency CSP-Rank for Motor Imagery-Based BCI System

Background. Due to the redundant information contained in multichannel electroencephalogram (EEG) signals, the classification accuracy of brain-computer interface (BCI) systems may deteriorate to a large extent. Channel selection methods can help to remove task-independent electroencephalogram (EEG) signals and hence improve the performance of BCI systems. However, in different frequency bands, brain areas associated with motor imagery are not exactly the same, which will result in the inability of traditional channel selection methods to extract effective EEG features. New Method. To address the above problem, this paper proposes a novel method based on common spatial pattern- (CSP-) rank channel selection for multifrequency band EEG (CSP-R-MF). It combines the multiband signal decomposition filtering and the CSP-rank channel selection methods to select significant channels, and then linear discriminant analysis (LDA) was used to calculate the classification accuracy. Results. The results showed that our proposed CSP-R-MF method could significantly improve the average classification accuracy compared with the CSP-rank channel selection method

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation